Press releases
August 11, 2021
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
Read more
June 30, 2021
First-in-Class, Oral Drug Candidate to be Evaluated in Randomized, Double-Blind, Placebo-Controlled Study in Patients with Debilitating Neurodegenerative Disease
Read more
April 21, 2021
The study’s enrollment target of 40 patients was exceeded in less than six weeks, highlighting the high demand for participation in the trial featuring a novel treatment approach for ALS. Based on this rapid patient enrollment, Retrotope expects data from the trial to be available by the end of 2021.
Read more
March 17, 2021
The first patient was dosed on March 10, with an additional eight patients enrolled during the study’s first week. Clinical investigators have already reported additional patient interest beyond the 40 subjects planned for the trial. As such, Retrotope expects the study to enroll rapidly, and data to be available by the end of 2021.
Read more
February 25, 2021
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug Designation by European Medicines Agency in INAD
Read more
February 11, 2021
Retrotope announced the appointment of Rick E Winningham as chairman of the company’s board of directors. Mr. Winningham, who currently serves as chairman and chief executive officer (CEO) of Theravance Biopharma, Inc., brings more than three decades of drug discovery, development, regulatory and commercialization experience in the global biopharmaceutical industry to his role as chairman.
Read more
August 14, 2020
Retrotope, a privately held, clinical-stage pharmaceutical company, today announced that Dr. Robert J. Molinari has stepped down as the company’s chief executive officer. In addition, Dr. Harry J. Saal has stepped down as the company’s chairman of the board. They will both continue to serve as non-executive members of the board of directors. An executive committee of the Board will manage day-to-day operations.
Read more
July 21, 2020
Retrotope starts IND enabling studies for its second deuterated polyunsaturated fatty acid (D-PUFA) drug candidate, targeting the treatment of AMD and related retinal pathologies
Read more
April 25, 2020
US FDA Allows Trial to Proceed for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP). Retrotope announced today that it received a “Study May Proceed” letter from US Food and Drug Administration (FDA) related to its recently filed Investigational New Drug (IND) application for the use of RT001 in the treatment of PSP. In addition, the FDA provided useful guidance and suggestions for detailed design elements of the trial.
Read more
April 16, 2020
Retrotope announced today that it has initiated experiments to determine if RT001, a drug that is able to downregulate pro-inflammatory fatty acid oxidation in a number of diseases, may provide benefits against COVID-19 initiated lung damage. The mechanisms by which COVID-19 causes severe illness and death in the elderly and in patients with pre-existing comorbid conditions is well documented.
Read more
February 18, 2020
Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug (RT001) for the treatment of Progressive SupraNuclear Palsy (PSP).
Read more
January 09, 2020
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA). Three clinical trials centers now open for enrollment; two additional ones initiating.
Read more